PBMEF Indicators

Are you on a successful path to ending tuberculosis (TB)? This group of indicators will help you answer that question by providing standardized comparisons across the United States Agency for International Development’s (USAID’s) TB priority countries. These indicators are intended to help measure each outcome and impact; help decision-makers answer questions; and measure progress towards global and individual country targets.

Contains example visualizations with real data.

Core Indicators

Reach

[BAC_CON (previously DT-12)] Percent Bacteriologically Confirmed

[CON_SCRN (previously CI-1)] Percent of Contacts Screened for TB

[DT_RT (previously DT-3)] TB Detection Rate (Treatment Coverage)

[MDR_NOTIF (previously RN-1)] RR/MDR-TB Notifications

[PEDS_NOTIF (previously CH-5)] Childhood TB Notifications

[PR_NOTIF (previously PR-1)] Private Sector TB Notifications

Cure

[DR_TSR (previously RS-1)] DR-TB Treatment Success Rate

[DS_TSR (previously SS-1)] DS-TB Treatment Success Rate

Prevent

[TPT_ENROLL (previously PT-1)] TPT Initiations

Sustain

[SN_DOMESTICR (previously SN-1)] Percent of TB Financing Received from Domestic Sources

Core Plus Indicators

Reach

[NEWREL_DST] Percent of People with New and Relapse TB with Drug Susceptibility Testing (DST)

[NEWREL_WRD (previously DT-15)] Rapid Diagnostic Testing at Time of Initial Diagnosis

[RET_DST] Percent of People with Previously Treated TB with Drug Susceptibility Testing (DST)

[XDR_NOTIF] Pre-XDR/XDR Notifications

Cure

[TX_DR_ADR (previously RS-6)] Number of People with Adverse Reactions to DR-TB Treatment

[TX_DR_ENROLL (previously RN-4)] DR-TB Treatment Initiations

[TX_LTR_ENROLL (previously RN-8)] DR-TB “All Oral” Longer Treatment Regimen Initiations

[TX_STR_ENROLL (previously RN-7)] DR-TB “All Oral” Short Treatment Regimen Initiations

Prevent

[TPT_COMPL] TPT Completions

[TPT_CON_ENROLL] TPT Initiations among Contacts

Sustain

[SN_TB_INSUR (previously SN-8B)] Existence of a National or Social Health Insurance System whose Benefit Package Includes TB Clinical Services

National Level Indicators

Reach

[DT_CI_INIT (previously CI-8)] Percent of People with Notified TB with a Contact Investigation Initiated

[DT_CON_DX (previously CI-4)] Number of Contacts Diagnosed with Active TB Disease

[DT_CON_PRES] Number of Contacts with Presumptive TB

[DT_CON_TST (previously CI-10)] Number of Contacts who Received TB Diagnostic Testing

[DT_CON_TX (previously CI-11)] Number of Contacts who Initiated TB Treatment

[PEDS_BAC_CON (previously CH-11)] Percent Children and Adolescents (0–14 years old) with New and Relapse Pulmonary TB who are Bacteriologically Confirmed

[PEDS_MDR_NOTIF (previously CH-13)] MDR-TB Notifications among Children and Adolescents (0-14 years)

Cure

[PEDS_TSR] Treatment Success Rate in Children and Adolescents (0-14 Years)

[PLHIV_TSR] Treatment Success Rate among PLHIV

[TX_DR_OUT_DIED (previously RS-2)] DR-TB Treatment Outcomes: Died

[TX_DR_OUT_FAIL (previously RS-3)] DR-TB Treatment Outcomes: Treatment Failed

[TX_DR_OUT_LOST (previously RS-4)] DR-TB Treatment Outcomes: Lost to Follow-Up (LTFU)

[TX_DR_OUT_NEVAL (previously RS-5)] DR-TB Treatment Outcomes: Not Evaluated

[TX_DS_ENROLL] DS-TB Treatment Initiations

[TX_DS_OUT_DIED (previously SS-2)] DS-TB Treatment Outcomes: Died during Treatment

[TX_DS_OUT_FAIL (previously SS-3)] DS-TB Treatment Outcomes: Treatment Failed

[TX_DS_OUT_LOST (previously SS-4)] DS-TB Treatment Outcomes: Lost to Follow-Up (LTFU)

[TX_DS_OUT_NEVAL (previously SS-5)] DS-TB Treatment Outcomes: Not Evaluated

Prevent

[TPT_CON_04 (previously PT-7)] Number of TPT Initiations among Contacts <5

[TPT_PLHIV_ENROLL (previously PT-8)] Number of TPT Initiations among PLHIV

Sustain

[SN_CQI] CQI Programs in Place

[SN_MQS] TB Drugs Meeting International Minimum Quality Standards

Project Level Indicators

Reach

[CON_TBI_POS (previously PS-6)] Number of Contacts Tested Positive for TBI

[CON_TBI_TST] Number of Contacts Tested for TBI

[DR_CI_INIT (previously CI-8B)] Percent of People with DR-TB who Had Contact Investigations Initiated

[DT_CXR (previously PS-7)] Number of People with Presumptive TB who Received a Chest X-ray (CXR)

[DT_PRES (previously PS-2)] Number of People with Presumptive TB

[DT_SCRN (previously PS-1)] Number of People Screened for TB

[DT_TST (previously PS-3)] Number of People with Presumptive TB who Received Diagnostic Testing

[DT_WRD (previously DT-14)] Number of People with Presumptive TB who were Tested with a Rapid Diagnostic Test

[MH_SCRN] Percent of People Diagnosed with TB and Screened for Mental Health Disorders

[NNS (previously AF-7)] Number Needed to Screen

[NNT (previously AF-8)] Number Needed to Test

[PR_BAC_CON] Percent Bacteriologically Confirmed in Private Sector

[TAT_RPRT (previously DT-32)] Turnaround Time (TaT): Percent of Specimens Tested and Results Reported to the Referring Facility (or Provider) within Specified Target Timeframe

[TAT_SUBMIT (previously DT-30)] Turnaround Time (TaT): Percent of Specimens Submitted to a Laboratory within Specified Target Timeframe

[TAT_TST (previously DT-31)] Turnaround Time (TaT): Percent of Specimens Received at Testing Laboratory and Tested within Specified Target Timeframe

Cure

[DM_SCRN_POS] Percent Screened Positive for Diabetes among People with Confirmed TB

[MH_TX] Percent of People with TB who Received Psychotherapeutic Interventions

[TX_DR_SUPPORT (previously RS-7)] Percent of People on DR-TB Treatment who Received Treatment Support

[TX_DS_SUPPORT (previously SS-7)] Percent of People on DS-TB Treatment who Received Treatment Support

Prevent

[DT_SCRN_COMM (previously PV-1)] Number of People Screened for TB Disease Outside of Health Facilities

[HCW_SCRN (previously HW-1)] Percent of HCWs Screened for TB

[HCW_TBI_POS (previously HW-6)] Percent of HCWs Diagnosed with TBI

[SN_IPC] Congregate Settings with IPC

[TPT_ADR] Number of People with Adverse Reactions to TPT

Sustain

[HCW_TRN] Percent of HCWs who Received TB-related Training

[SN_STGMA_ASSESS (previously SN-32B)] TB Stigma Assessment/Gap Analysis Available

[SN_STGMA_NSP (previously SN-32A)] TB Stigma Reduction in NSP

[STKOUT_FLD (previously SN-42)] Stockout of Any First-line TB Treatment Drugs

[STKOUT_SLD (previously SN-43)] Stockout of Any Second-line TB Treatment Drugs

[STKOUT_WRD (previously SN-44)] Stockout of TB Rapid Molecular Tests and Related Commodities

Extended Indicators

Active Case Finding (AF)

[AF-1] Number of Individuals Eligible for Screening

[AF-2] Number of Individuals Screened for TB

[AF-4] Number of Presumptive TB Cases Identified

[AF-5] Number of Presumptive TB Cases Tested for TB

[AF-6] Number of Presumptive TB Cases with Confirmed TB

[AF-9] Number with Confirmed TB Starting Appropriate Treatment

[AF-3] Screening Coverage among Risk Groups

Childhood TB (CH)

[CH-23] Childhood DR-TB (Ages 0-14) Treatment Outcome: Died

[CH-22] Childhood DR-TB (Ages 0-14) Treatment Success Rate

[CH-26] Childhood DR-TB Treatment Outcome: Not Evaluated

[CH-8] Childhood TB (0-4) Notifications

[CH-9] Childhood TB (5-14) Notifications

[CH-7] Childhood TB Detection

[CH-3] Children (0-14 years) Clinically Evaluated for TB

[CH-1] Estimated Number of TB Cases among 0-14-year-old Children

[CH-2] Estimated Number of TB Deaths among 0-to-14-year-old Children

[CH-21] Number of Childhood DR-TB (Ages 0-14) Who Were Enrolled on Appropriate DR-TB Treatment by Regimen during a Specified Period

[CH-12] Percent of Notified New and Relapse Extrapulmonary TB Notifications (0-14 years-old) with Bacteriological Confirmation

[CH-6] Percentage of New and Relapse TB Case Notifications That Are among 0-14-year-old Children, Calculated at National and Subnational Level

[CH-10] Ratio of 0-4 to 5-14 years-old Notifications

[CH-29] Stockouts of Child-friendly Formulations for TB Treatment, by Year and Length of Stockout

[CH-17] Treatment Outcome for Childhood TB (Ages 0-14): Died

[CH-19] Treatment Outcome for Childhood TB (Ages 0-14): Lost to Follow-up (LTFU)

[CH-20] Treatment Outcome for Childhood TB (Ages 0-14): Not Evaluated

[CH-18] Treatment Outcome for Childhood TB (Ages 0-14): Treatment Failed

[CH-14] Treatment Success Rate for Childhood TB (Ages 0-14)

[CH-15] Treatment Success Rate for Childhood TB (Ages 0-4)

[CH-16] Treatment Success Rate for Childhood TB (Ages 5-14)

[CH-27] Use of Child-friendly Formulations for TB Treatment, First-line Drugs (Yes/No)

[CH-28] Use of Child-friendly Formulations for TB Treatment, Second-line Drugs (Yes/No)

Contact Investigation (CI)

[CI-12] Contacts Screened Negative for TB

[CI-2] Estimated Average Number of Household Contacts Identified per One Notified New and Relapse Bacteriologically Confirmed Pulmonary TB Case

[CI-7] Percent of Close Contacts who Tested Positive for TBI

[CI-5] Percent of Contacts Detected with DR-TB Disease through Contact Investigation of DR-TB Index Case

[CI-6] Percent of Contacts Detected with DS-TB Disease through Contact Investigation of DR-TB Index Case

[CI-3] Percent of Contacts Evaluated for TB Disease

[CI-9] Percent of Identified Contacts Investigated

Drug-Resistant TB Notifications (RN)

[RN-2] DR-TB Case Detection

[RN-5] DR-TB Treatment Enrollment Coverage

[RN-6] Number of Treatment Sites Providing DR-TB Treatment

[RN-3] Percent of Notified RR/MDR-TB Cases with DST Results for Second-line TB Drugs

Drug-Resistant TB Treatment Success (RS)

[RS-8] Treatment Success Rate for DR-TB/HIV Coinfected Patients

Healthcare Worker Screening (HW)

[HW-9] Contacts: HCWs Who Were Ruled Out for TB Disease, and Are Eligible Household Contacts

[HW-10] Contacts: HCWs Who Were Ruled Out for TB Disease, Are Eligible Household Contacts, and Were Initiated on TPT

[HW-13] HCWs Who Completed TPT

[HW-4] HCWs Who Were Ruled Out for TB Disease

[HW-3] Percentage of HCWs Diagnosed with TB Disease

[HW-2] Percentage of HCWs Screened Positive for TB

[HW-5] Percentage of HCWs Tested for TBI

[HW-7] PLHIV: HCWs Who Were Ruled Out for TB Disease, and are PLHIV

[HW-8] PLHIV: HCWs Who Were Ruled Out for TB Disease, are PLHIV, and Were Initiated on TPT

[HW-11] TBI-positive: HCWs Who Were Ruled Out for TB Disease, and Are Neither PLHIV nor Eligible HH Contacts, and Tested Positive for TBI during the Reporting Period

[HW-12] TBI-positive: HCWs Who Were Ruled Out for TB Disease, Are Neither PLHIV nor Eligible Household Contacts, Tested Positive for TBI and Were Initiated on TPT

Presumptive TB (PS)

[PS-8] Number of Health Facilities Reporting on Number of Presumptive TB Patients during the Reporting Period

[PS-4] Number of Presumptive TB Patients Diagnosed with TB Disease

[PS-5] Number of Presumptive TB Patients Who Were Ruled Out for TB Disease and Tested for TBI

Prevention (PV)

[PV-2] Number of Contacts of Bacteriologically Confirmed Pulmonary TB Cases who Were Screened for TB Infection (and/or Tested for TBI) According to National Screening Protocols during the Specified Reporting Period

[PV-3] Number of Eligible (Ruled Out for TB Disease) Individuals Who Started Treatment for TB Infection during the Reporting Year

[PV-4] Number of Individuals Who Completed Treatment for TBI during the Reporting Period

Private Sector (PR)

[PR-4] Percentage of Notified DR-TB Cases Contributed by Private Sector

[PR-2] Percentage of Notified TB Cases Contributed by Private Sector

[PR-3] Percentage of Privately Notified Pulmonary Cases with Bacteriologically Confirmed TB

[PR-5] Percentage of Privately Notified Pulmonary Cases with Confirmed Result on Rifampicin Sensitivity

[PR-7] Treatment Success Rate of DR-TB Cases Enrolled on Treatment in Private Sector

[PR-6] Treatment Success Rate of TB Cases Notified by Private Sector

Sustainability (SN)

[SN- 37A] A – Inclusiveness of NGOs in Social Contracting

[SN- 39A] A – NTP Consults with TB Civil Society/TB Survivors to Review Progress

[SN- 41A] A – NTP Staff Undertake TB and Gender Sensitization/Training

[SN-25] Annual Budget of NTP is Publicly Available

[SN-30] Anti DR-TB Drug Availability for Patients for Free

[SN-29] Anti DR-TB Drugs Listed on the Country’s National Essential Medicines List (NEML)

[SN-33] Approval Process Efficiency

[SN- 33A] Approval Process Efficiency – A

[SN- 33B] Approval Process Efficiency-B

[SN- 26B] Availability of Final JPR/JMM Report

[SN- 37B] B – Inclusiveness of Private Sector in Social Contracting

[SN- 41B] B – Male-Female Ratio of NTP and Provincial Managers

[SN- 39B] B – NTP Invites TB Civil Society/TB Survivors to Participate in JPR/JMM/External Reviews

[SN- 39C] C – NTP Consults with Civil Society and TB Survivors to Develop the NSP and Donor Proposals

[SN- 41C] C – TB Gender Assessment Report

[SN-6] Capacity of NTP for Absorption of Domestic Funding (In Reporting Year)

[SN-7] Capacity of NTP for Absorption of Funds from GF

[SN-22] Case Notification Data Publicly Available on NTP Website/MOH

[SN-10] Catastrophic Costs Related to TB Care

[SN- 40A] Community (Not Organized) Feedback Obtained

[SN- 39D] D – Civil Society/TB Survivors Involved in TB Research Development/Planning, Implementation, and Dissemination

[SN- 41D] D – NSP Highlights Gender Inclusiveness in TB Services and Programs

[SN-4] Domestic Funding for Drugs

[SN-5] Domestic Funding for Lab Commodities

[SN- 41E] E – Women TB Survivors Included in any NTP Event in Reporting Year

[SN-36] Effective NTP Capacity

[SN- 36C] Effective NTP Capacity in Relation to Number of Provinces

[SN- 36A] Effective NTP Capacity in Relation to Population

[SN- 36B] Effective NTP Capacity in Relation to TB Burden

[SN- 41F] F – Gender Disaggregated Data for Treatment Outcome Available for Most Recent Reported Cohort

[SN-45] First-line TB Treatment Drugs Past Expiration

[SN-39] Inclusiveness of Civil Society/TB Survivors

[SN-40] Inclusiveness of Community (Not Organized) and Subnational Entities

[SN-41] Inclusiveness of Gender

[SN-38] Inclusiveness of Key Populations (KPs)

[SN- 26A] JPR/JMM was Conducted Recently

[SN-28] Mandatory Notification

[SN-13] New WHO DR-TB Treatment Guidelines

[SN-16] Non-admission to Initiate DR-TB Treatment

[SN-35] NTP Capacity

[SN-34] NTP Manager Empowerment in the Organizational Hierarchy

[SN-21] NTP Ownership of Tools for Public Visibility

[SN-27] Partnership Statement Adoption and Implementation

[SN-14] Pediatric TB Treatment

[SN-3] Percent of TB Financing Received from Domestic Sources

[SN-9] Percent of TB Patients Covered by Insurance

[SN-20] Regimen for TBI

[SN-47] Replenishable TB Diagnostic Products Past Expiration

[SN-46] Second-line TB Treatment Drugs Past Expiration

[SN-15] Self-administered DS-TB Treatment

[SN-37] Social Contracting with Govt. Funds (NGOs/ Private Sector)

[SN-8] Social Protection

[SN-8A] Social Protection Scheme Available

[SN-17] Special Social Support for DR-TB Treatment

[SN-26] Status of TB Joint Program Review (JPR) or Joint Monitoring Mission (JMM)

[SN-48] Stockouts of Child-friendly Formulations for TB Treatment

[SN- 40B] Subnational Government Entities Feedback Obtained

[SN-24] TB NSP Publicly Available on the NTP Website/Web Page

[SN-18] TB Screening

[SN-23] TB Technical Guidelines Publicly Available on the NTP Website/MOH

[SN-31] TB Training Module/Guidance Contain Information on Human Rights Issues

[SN-19] TBI TPT

[SN-2] Total Funding Received for TB

[SN-12] Universal DST

[SN-11] Use of Rapid Molecular Diagnostic Testing (WHO-recommended Rapid Test) WRD

TB Detection (DT)

[DT-7] Number of Facilities Reporting Extrapulmonary TB Cases

[DT-28] Number of Laboratory-confirmed TB Cases That Are Resistant to Rifampicin and Resistant to Any Fluoroquinolone (pre-XDR-TB or XDR-TB)

[DT-5] Number of Notified Extrapulmonary TB (New and Relapse) Bacteriologically Confirmed

[DT-6] Number of Notified Extrapulmonary TB (New and Relapse) Clinically Diagnosed

[DT-4] Percent of Extrapulmonary TB Cases Notified

[DT-11] Percent of Health Facilities Implementing Intensified Case Finding (i.e., Using Standard of Practice)

[DT-26] Percent of INH Monoresistance (Previously Treated Including Relapse)

[DT-25] Percent of New TB Patients with INH Monoresistance

[DT-18] Percent of New TB Patients with Rifampicin Monoresistance

[DT-9] Percent of Prisons Conducting Regular Screening for TB According to National Policy

[DT-10] Percent of Prisons Conducting Screening for TB with Chest X-ray

[DT-34] Percent of Rapid Diagnostic Testing of New and Relapse TB Cases

[DT-20] Percent of Rifampicin Monoresistance (New and Previously Treated Including Relapse)

[DT-19] Percent of Rifampicin Monoresistance (Previously Treated Including Relapse)

[DT-8] Percent of Total Cases Notified that Were Referred or Diagnosed Via Community-based Approaches (Outside of Health Facilities) in the Basic Management Units with Data on Referrals by Community Health Workers

[DT-27] Percent of Total INH Monoresistance (New and Previously Treated Including Relapse)

[DT-13] Percent of WHO-recommended Rapid Diagnostic (WRD) Testing Sites that Are Included in a Quality Assurance Program

[DT-29] Proportion of Presumptive TB Patients Identified during the Reporting Period with Specimen Collected within Specified Target Timeframe

[DT-33] Proportion of Results Reported and Patients Initiated on Treatment during the Reporting Period within Specified Target Timeframe

[DT-2] TB Case Notification Rate (CNR)

[DT-1] TB Case Notifications

[DT-21] TB Patients with Available DST Results for Isoniazid and Rifampicin

[DT-24] TB Patients with Resistance to Both Isoniazid and Rifampicin (DR-TB)

[DT-17] TB Patients with Resistance to Rifampicin (RR-TB)

[DT-16] TB Patients with Test Results for Rifampicin

[DT-22] TB Patients with Test Results for Rifampicin and Isoniazid and with Resistance to Isoniazid

[DT-23] TB Patients with Test Results for Rifampicin and Isoniazid and with Resistance to Rifampicin

TB Preventive Treatment (PT)

[PT-4] Number of Adult Household Contacts and Contacts > 5 Years Started on TPT

[PT-3] Number of Children (< 5 Years) Household Contacts Started on TPT

[PT-2] Number of Household Contacts Started on TPT

[PT-5] Number of PLHIV Started on TPT

[PT-11] Percent of Adult Household Contacts (and Contacts > 5 Years) Completed TPT

[PT-10] Percent of Children (< 5 Years) Household Contacts Completed TPT

[PT-9] Percent of Household Contacts Completed TPT

[PT-6] Percent of Household Contacts Started on TPT

[PT-12] Percent of PLHIV Completed TPT

[PT-15] Percent TPT Patients Developed TB during TPT

[PT-14] Percent TPT Patients Interrupted Due to ADR

[PT-13] Percent TPT Patients LTFU

[PT-16] Percent TPT Patients with Baseline AST/ALT Tests

TB Treatment Success (SS)

[SS-6] Treatment Success Rate for TB/HIV Coinfected Patients

TB/HIV (TH)

[TH-26] DR-TB/HIV Coinfected Treatment Outcome: LTFU

[TH-27] DR-TB/HIV Coinfected Treatment Outcome: Not Evaluated

[TH-25] DR-TB/HIV Coinfected Treatment Outcome: Treatment Failed

[TH-24] DR-TB/HIV Coinfection Treatment Outcome: Died during Treatment (Expressed as Percentage)

[TH-16] Percent of DR-TB Patients Recorded as HIV-positive

[TH-15] Percent of DR-TB Patients with Known HIV Status

[TH-17] Percent of DR-TB/HIV Coinfected Patients Enrolled on Appropriate DR-TB Treatment

[TH-19] Percent of HIV-positive DR-TB Patients Started or Continued on ART

[TH-18] Percent of HIV-positive TB Patients Started or Continued on ART

[TH-5] Percent of PLHIV Enrolled on ART and Tested Positive for TB Disease, Who Were Enrolled on TB Treatment

[TH-1] Percent of PLHIV Enrolled on ART Screened for TB Disease

[TH-4] Percent of PLHIV Enrolled on ART Who Tested Positive for TB Disease

[TH-6] Percent of PLHIV Enrolled on ART, Screened Negative for TB Disease

[TH-2] Percent of PLHIV Enrolled on ART, Screened Positive for TB Disease

[TH-3] Percent of PLHIV Enrolled on ART, Tested for TB Disease

[TH-7] Percent of PLHIV Enrolled on ART, Tested for TBI

[TH-8] Percent of PLHIV Enrolled on ART, Tested Positive for TBI

[TH-10] Percent of PLHIV on TPT Developed TB during TPT

[TH-11] Percent of PLHIV on TPT, and TPT Interrupted due to Adverse Drug Reaction (ADR)

[TH-12] Percent of PLHIV on TPT, with Baseline AST/ALT Tests

[TH-9] Percent of PLHIV on TPT: LTFU

[TH-14] Percent of TB Patients Recorded as HIV-positive

[TH-13] Percent of TB Patients with Known HIV Status

[TH-28] PLHIV with TB Who Have CD4 > 100

[TH-29] PLHIV with TB Who Have CD4 > 350

[TH-30] PLHIV with TB who have viral load testing every 6 months

[TH-20] TB/HIV Coinfected Treatment Outcome: Died during Treatment (Expressed as Percentage)

[TH-22] TB/HIV Coinfected Treatment Outcome: LTFU

[TH-23] TB/HIV Coinfected Treatment Outcome: Not Evaluated

[TH-21] TB/HIV Coinfected Treatment Outcome: Treatment Failed